Radiation Oncology Journal

  • 제23권2호
  • /
  • Pages.98-105
  • /
  • 2005
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지

근치적 방사선치료를 시행한 제2기의 자궁경부암 환자에서 p53과 Bax의 발현과 임상적 의의

Evaluation of p53 and Bax Expression as Prognostic Markers in Invasive Cervical Carcinoma Stage IIB Patients Treated with Radiation Therapy

  • 최석진 (인하대학교 의과대학 병리학교실) ;
  • 김헌정 (인하대학교 의과대학 방사선종양학교실) ;
  • 송은섭 (인하대학교 의과대학 산부인과학교실) ;
  • 김창영 (샘안양병원 산부인과) ;
  • 이미조 (인하대학교 의과대학 방사선종양학교실) ;
  • 김우철 (인하대학교 의과대학 방사선종양학교실) ;
  • 노준규 (인하대학교 의과대학 방사선종양학교실)
  • Choi Sukjin (Department of Pthology, Inha University Medical College) ;
  • Kim Hunjung (Department of Radiation Oncology, Inha University Medical College) ;
  • Song Eunseop (Department of Obstetrics and Gynecology, Inha University Medical College) ;
  • Kim Changyoung (Department of Obstetrics and Gynecology, Sam Hospital) ;
  • Lee Meejo (Department of Radiation Oncology, Inha University Medical College) ;
  • Kim Woochul (Department of Radiation Oncology, Inha University Medical College) ;
  • Loh John J. K. (Department of Radiation Oncology, Inha University Medical College)
  • 발행 : 2005.06.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적 : 진행된 자궁경부암 환자에서 bax와 p53의 발현 빈도를 방사선치료를 받은 환자를 대상으로 예후인자로서의 유용성을 알아보기 위하여 덜 연구를 시행하였다. 대상 및 방법 : 본 연구는 1996년 6월부터 2003년 12월까지 근치적 방사선치료를 받은 FIGO stage IIb의 자궁 경부암 환자 65명을 대상으로 면역조직화학 염색을 시행하여 관찰된 bax와 p53의 발현과 환자의 5년 생존율과 무병생존율의 관계를 연구하였다. 대상 및 방법 : 대상환자 65명에 대한 5년 생존율과 무병생존율은 각각 $65.1\%$와 $62.9\%$였다. p53에 대한 면역조직화학염색은 $26.2\%$의 발현을 보였으며, 음성 환자 군과 양성 환자 군의 5년 생존율은 각각 $66.6\%$와 $61.1\%$ (p=0.176)였으나, 무병생존율은 각각 $72.1\%$와 $50.9\%$ (p=0.027)로 단변량분석에서 통계학적 차이를 보였다. 면역염색에 대한 bax의 발현은 $52.3\%$에서 양성을 보였으며, 음성 환자 군과 양성 환자 군의 5년 생존율은 각각 $68.8\%$와 $63.6\%$ (p=0.726)였으며, 무병생존율은 각각 $68.1\%$와 $64.1\%$ (p=0.505)로 통계학적 차이가 없었다. 다변량분석에서는 p53 단백의 발현과 bax의 발현이 생존율에 의미 있는 영향을 주지 못했다. 그러나 ps3+/bax-의 면역화학염색 결과를 보인 9명의 환자에서 의미 있는 가장 낮은 무병생존율을 관찰할 수 있었다. 결론 : p53과 bax의 발현은 단독적으로 방사선치료를 시행한 환자에서 유의성을 가지는 예후인자로 사용할 수 없었다. 그러나 p53과 bax의 발현을 동시에 평가할 경우 유용한 예후 인자로서 임상적 유용성이 있을 것으로 생각한다.

Purpose : The objective of our study was to evaluate the immunohistochemical expression of p53 and bax proteins as prognostic markers in FIGO stage IIb invasive squamous cell carcinoma of the uterine cervix. Materials and Methods : Sixty-five cases of squamous cell carcinoma of the cervix (stage IIb) that were diagnosed from October 1995 to December 2003 were analyzed retrospectively for the bax and p53 expression. These expressions were determined immunohistochemically and they were correlated to the patients' overall survival and disease-free survival. Results : The overall 5-year survival (OS) rate and the disease-free survival (DFS) rate were $65.1\%$ and $62.9\%$, respectively. p53 and bax immunoreactivity was seen in $26.2\%$ and $52.3\%$ of cases, respectively, with variable levels of expression. On the univariate analysis, only p53 positivity correlated with poor survival in DFS (log-rank test p=0.027), but this significance was not maintained on multivariated analysis by Cox's regression. The nine cases with the immunophenotype ps3+/bax- had the poorest survival. Conclusion : Neither p53 nor bax expression are Independent predictors of the prognosis for stage IIb cervical squamous cancers. Evaluation of p53 and bax co-expression may affect the clinical outcome and further investigation is needed.

키워드

참고문헌

  1. 2002 Annual Report of the Korea Central Cancer Registry, Ministry of Health and Welfare Republic of Korea
  2. Toita T, Nakano M. Higashi M. Sakumoto K, Kanazawa K. Prognostic value of cervical size and pelvic lymph node status assessed by computed tomography for patients with uterine cervical cancer treated by radical radiation therapy. Int J Radiat Oncol Biol Phys 1995;843-849 https://doi.org/10.1016/0360-3016(95)00204-5
  3. Ohara K. Tanaka YO. Tsunoda. et al. Nonoperative assessment of nodal status for locally advanced cervical squamous cell carcinoma treated by radiotherapy with regard to patterns of treatment failure. Int J Radiat Oncol Biol Phys 2003;55:354-361 https://doi.org/10.1016/S0360-3016(02)03930-5
  4. Eifel PJ. Morris M, Wharton JT. Oswald MJ. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1994;29:9-16 https://doi.org/10.1016/0360-3016(94)90220-8
  5. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-849 https://doi.org/10.1038/362847a0
  6. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Location of gene for human p53 tumour antigen to band 17p13. Nature 1986;320:84-85 https://doi.org/10.1038/320084a0
  7. Hall PA, Meek D, Lane DP. p53-integrating the complexity. J Pathol 1996;180:1-5 https://doi.org/10.1002/(SICI)1096-9896(199609)180:1<1::AID-PATH712>3.0.CO;2-U
  8. EI-Deiry WS, Harper JW, O'Connor PM, et al. WAF/ CIPI in p53-mediated G1 arrest and apoptosis. Cancer Res 1994:54:1169-1174
  9. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88:386-401
  10. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-1132 https://doi.org/10.1126/science.275.5303.1129
  11. Miyashita T, Krajewski S, Kraiewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-1805
  12. Liang XH, Mungal S, Ayscue A, et al. Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 1995:57:509-521 https://doi.org/10.1002/jcb.240570316
  13. Ishikawa H, Mitsuhashi N, Sakurai H, Maebayashi K, Niibe H. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone. Cancer 2001;91:80-89 https://doi.org/10.1002/1097-0142(20010101)91:1<80::AID-CNCR11>3.0.CO;2-E
  14. Ebara T, Mitsuhashi N, Saito Y, et al. Prognostic significance of immunohistochemically detected p53 protein expression in stage IIIB squamous cell carcinoma of the uterine cervix treated with radiation therapy alone. Gynecol Oncol 1996;63:216-218 https://doi.org/10.1006/gyno.1996.0309
  15. Jaros E, Perry RH, Adam L, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumors. Br J Cancer 1992;66:373-385 https://doi.org/10.1038/bjc.1992.273
  16. Awwad S, Jaros E, Somes J, Lunec J. P53 overexpressian in head and neck carcinoma and radiotherapy results. Int J Radiat Oncol Biol Phys 1996;34:323-332 https://doi.org/10.1016/0360-3016(95)02108-6
  17. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206 https://doi.org/10.1093/jnci/85.3.200
  18. Harris M, Metcalf RA, Welsh A, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Scc USA 1990;887:9958-9961
  19. Iwava K, Tsuda H, Hiraide H, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991;82:835-840 https://doi.org/10.1111/j.1349-7006.1991.tb02710.x
  20. Tjalma W, De Cuyper E, Weyler J, et al. Expression of bcl-2 in invasive and in situ carcinoma of the uterine cervix. Am J Obstet Gynecol 1998;178:113-117 https://doi.org/10.1016/S0002-9378(98)70636-2
  21. Stehman FB, Bundy BN, Disasia PJ, Keys HM, Larson JE. Fowler WC. Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991;67:2776-2785 https://doi.org/10.1002/1097-0142(19910601)67:11<2776::AID-CNCR2820671111>3.0.CO;2-L
  22. Kristensen GB. Abeler VM. Risberg B. Trope C. Bryne M. Tumor size. depth of invasion and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma. Gynecol Oncol 1999;74:245-251 https://doi.org/10.1006/gyno.1999.5420
  23. Kim HJ. Kim WC. Lee MJ. Kim CS. Song ES. Loh JK. Comparison of the result of radiation alone and radiation with daily low dose cisplatin in management of locally advanced cervical cancer. J Korea Soc Ther Radiol Oncol 2004;22:200-207
  24. Harris CC. Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-1327 https://doi.org/10.1056/NEJM199310283291807
  25. Hall PA. Lane DP. P53 in tumour pathology: can we trust immunohistochemistry?-Revisited! J Pathol 1994;172:1-4 https://doi.org/10.1002/path.1711720103
  26. Marchetti A. Buttitta F. Merlo G. et al. p53 alterations in non-small cell lung cancers correlated with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 1993;53:2864-2851
  27. Skirnisdottir I. Seidal T. Gerdin E. Sorbe B. The prognostic importance of p53. bcl-2. and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer 2002;12:265-276 https://doi.org/10.1046/j.1525-1438.2002.01121.x
  28. l.ipponan P. Ji H. Aaltomaa S. Syrianen S. Syrianen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 1993;55:51-56 https://doi.org/10.1002/ijc.2910550110
  29. Couture G. Raybaud-Diogene H. Tetu B. et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002;94:713-722 https://doi.org/10.1002/cncr.10232
  30. Oka K. Nakano T. Arai T. p53CM1 expression is not associated with prognosis in uterine cervical carcinoma. Cancer 1993;72:160-164 https://doi.org/10.1002/1097-0142(19930701)72:1<160::AID-CNCR2820720130>3.0.CO;2-C
  31. Gitsch G. Kainz C. Joura E. Breitenecker G. Mutant p53 product in patients with stage III cervical cancer. Anticancer Res 1992;12:2241-2242
  32. Kainz C. Kohlberger P. Gitsch G. Sliutz G. Breitenecker G. Reinthaller A. Mutant p53 in patients with invasive cervical cancer stage IB to IIB. Gynecol Oncol 1995;57:212-214 https://doi.org/10.1006/gyno.1995.1127
  33. Holm R. Skomedal H. Helland P. Kristensen G. Borresen AL. Nesland JM. Immunohistochemical analysis of p53 protein overexpression in normal. premalignant. and malignant tissue of the cervix uteri. J Pathol 1993;169:21-26 https://doi.org/10.1002/path.1711690105
  34. Raikumar T. Haian S. Baruah RK. Majhi U. Selvaluxmi G. Vasanthan A. Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. Eur J Gynaecol Oncol 1998;19:556-560
  35. Pillai MR. Jayacrakash PG. Nair MK. Bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma. J Cancer Res Clin Oncol 1999;125:55-60 https://doi.org/10.1007/s004320050242
  36. Jain D. Srinivasan R. Patel FD. Kumari Gupta S. Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol 2003;88:22-28 https://doi.org/10.1006/gyno.2002.6838
  37. Dimitrakakis C. Kymionis G. Diakomanolis E. et al. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol Oncol 2000;77:129-136 https://doi.org/10.1006/gyno.1999.5715
  38. Werness BA. Levine AJ. Howley PM. Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 1990;248:76-79 https://doi.org/10.1126/science.2157286
  39. Park TW. Fujiwara H. Wright TC. Molecular biology of cervical cancer and its precursors. Cancer 1995:76:1902-1913 https://doi.org/10.1002/1097-0142(19951115)76:10+<1902::AID-CNCR2820761306>3.0.CO;2-0
  40. Chittenden T. Harrington EA. O'Connor R. et al. Induction of apoptosis of the Bcl-2 homologue Bak. Nature 1995;374:733-736 https://doi.org/10.1038/374733a0
  41. Wootipoom V. Lekhyananda N. Phungrassami T. Boonyaphiphat P. Thongsuksai P. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecol Oncol 2004;94:636-642 https://doi.org/10.1016/j.ygyno.2004.03.012
  42. Crawford RA, Caldwell C. Iles RK. Lowe D. Shepherd JH. Chard T. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br J Cancer 1998;78:210-214 https://doi.org/10.1038/bjc.1998.466
  43. Tjalma WA, Weyler JJ. Bogers JJ, et al. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2001;97:223-230 https://doi.org/10.1016/S0301-2115(00)00541-8
  44. Harima Y. Harima K, Shikata N. Oka A. Ohnishi T, Tanaka Y. Bax and bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol 1998;124:503-510 https://doi.org/10.1007/s004320050206
  45. Mukherjee G, Freeman A. Moore R, et al. Biologic factors and response to radiotherapy in carcinoma of the cervix. Int J Gynecol Cancer 2001:11:187-193 https://doi.org/10.1046/j.1525-1438.2001.01014.x
  46. Chung TK. Cheung TH, Lo WK, et al. Expression of apoptotic regulators and their significance in cervical cancer. Cancer Lett 2002;180:63-68 https://doi.org/10.1016/S0304-3835(01)00842-4
  47. Korsmever SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-886
  48. Lipponen PK, Aaltomaa S, Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumors. Histopathology 1996;28:135-140 https://doi.org/10.1046/j.1365-2559.1996.276322.x
  49. Bubendorf L, Sauter G, Moch H, et al. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996;148:1557-1565
  50. Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrianen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with a favourable prognosis. J Pathol 1995;177:49-55 https://doi.org/10.1002/path.1711770109
  51. Diebold J, Baretton G, Felchner M, et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996;105:341-349 https://doi.org/10.1093/ajcp/105.3.341
  52. Spafford M F, Koeppe J, Pan Z, Archer PG, Mevers AD, Franklin WA. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1996;122:627-632 https://doi.org/10.1001/archotol.1996.01890180035010
  53. Halder S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-2097
  54. Chiou SK, Rao I, White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 1994;14:2556-2563 https://doi.org/10.1128/MCB.14.4.2556
  55. Oltvai ZN, Milliman CL, Korsmever SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619 https://doi.org/10.1016/0092-8674(93)90509-O
  56. Henriksen R, Wilander E, Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumors. Br J Cancer 1995;72:1324-1329 https://doi.org/10.1038/bjc.1995.509
  57. Jain D, Srinivasan R, Patel FD, Kumari Gupta S. Evaluation of p53 and Bcl-2 expression as prognostic marker in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol 2002;88:22-28 https://doi.org/10.1006/gyno.2002.6838